Hypertension - Outpatient Management
~50% of US adults have HTN, and it's the #1 modifiable cardiovascular risk factor. Diagnosis, workup, drug selection by compelling indication, resistant-HTN evaluation, and SPRINT-era BP targets. For acute hypertensive emergency, see HTN Emergency.
🔍 Overview
Staging (ACC/AHA 2017)
| Category | SBP (mmHg) | DBP (mmHg) | Action |
|---|---|---|---|
| Normal | < 120 | < 80 | Reassess in 1 year. No drugs. |
| Elevated | 120-129 | < 80 | Lifestyle only. Reassess in 3-6 months. No drugs. |
| Stage 1 | 130-139 | OR 80-89 | Lifestyle. Single-drug monotherapy if ASCVD risk ≥ 10%, established CV disease, DM, or CKD. |
| Stage 2 | ≥ 140 | OR ≥ 90 | Lifestyle plus pharmacotherapy. Two-drug combination upfront if SBP ≥ 20 or DBP ≥ 10 above target (most stage 2 patients). Single-pill combinations preferred for adherence. |
| Resistant HTN | BP above goal at any threshold | BP above target despite 3 drugs of different classes (one a diuretic) at maximally tolerated doses, OR controlled BP requiring 4+ drugs. Rule out pseudoresistance first; then secondary causes; then add spironolactone as the 4th agent (PATHWAY-2). See Resistant HTN tab. | |
| Hypertensive urgency | > 180 | OR > 120 | NO end-organ damage. Asymptomatic or mild headache only. Outpatient management: restart or up-titrate home oral meds, lower BP gradually over 24-72 hours. NO IV agents; no ICU. Rapid lowering causes watershed strokes. |
| Hypertensive emergency | > 180 | OR > 120 | WITH end-organ damage (CNS, cardiac, renal, retinal). ICU. IV nicardipine or labetalol. Lower MAP by ≤ 25% in the first hour. See HTN Emergency. |
Diagnosis requires confirmation. Two or more elevated readings on separate occasions, or home/ambulatory monitoring confirming the office reading. Single-visit diagnosis misses white-coat HTN (over-treats) and masked HTN (under-treats).
Why It Matters
- Most common modifiable CV risk factor. Affects ~50% of US adults, and a higher fraction of older adults.
- Risk doubles for every 20/10 mmHg above 115/75. Linear, log-linear relationship with stroke, MI, HF, CKD, dementia.
- Asymptomatic until end-organ damage occurs. Patients don't feel HTN. Adherence is the central battle.
- Black patients develop HTN earlier, with more severe target-organ damage and lower response to ACEi/ARB monotherapy. Thiazide or CCB first-line.
Primary vs Secondary HTN
- Primary (essential) HTN -~90-95%. Multifactorial: genetics, age, salt sensitivity, obesity, sympathetic tone.
- Secondary HTN -~5-10%. Identifiable cause. Higher prevalence in atypical presentations: onset < 30 or sudden onset > 65, severe or resistant HTN, abrupt change in stable HTN, target-organ damage out of proportion.
Top secondary causes to think about: primary aldosteronism (most common, ~5-13% of HTN, often normokalemic), obstructive sleep apnea, renovascular disease, CKD, pheochromocytoma, Cushing's syndrome, thyroid disease, oral contraceptives / NSAIDs / decongestants. See the Resistant HTN tab for the workup algorithm.
🧪 Workup
Confirming the Diagnosis
- Office BP technique matters. Patient seated quietly 5 minutes, feet on floor, arm at heart level, no caffeine/exercise/smoking 30 min prior, appropriate cuff size (cuff too small = falsely high). Two readings, 1-2 minutes apart, average them.
- Confirm with out-of-office monitoring when possible. Home BP monitoring (HBPM) is most practical; 24-hour ambulatory BP monitoring (ABPM) is the gold standard.
- White-coat HTN -elevated office, normal home/ABPM. Don't treat with drugs; monitor.
- Masked HTN -normal office, elevated home/ABPM. Treat. Higher CV risk than white-coat.
Initial Labs & Studies
| Test | Reason We Check | What It Changes / Specific Findings |
|---|---|---|
| BMP | Baseline kidney function + drug-safety screen + flag for secondary HTN | eGFR < 60 = stage 3 CKD: tightens BP target to < 130/80, makes ACEi/ARB a compelling (renal-protective) indication, and triggers dose-adjustment for renally cleared drugs (atenolol, nadolol, lisinopril). eGFR < 30: HCTZ/chlorthalidone become ineffective (switch to loop or metolazone) and MRAs become dangerous (hyperK risk). K⁺ < 3.5 unprovoked → primary aldosteronism until proven otherwise (workup with morning aldosterone-renin ratio). K⁺ > 5.0: hold MRA, reduce or hold ACEi/ARB. Bicarb low + K⁺ high in a diabetic with CKD: think Type 4 RTA. Always check K⁺ before starting any RAAS blocker or thiazide. |
| Fasting lipids | Required input for the ASCVD calculator + screen for statin indication + flag metabolic syndrome | The ASCVD 10-year risk score literally needs lipid values to compute -the Pooled Cohort Equation requires total cholesterol and HDL. Without them you can't risk-stratify. The score then determines stage 1 HTN management: treat with drugs if ASCVD ≥ 10%, lifestyle alone if < 10%. Lipids also independently identify statin indications: LDL ≥ 190 (high-intensity statin), DM age 40-75 (moderate-to-high), ASCVD ≥ 7.5% (moderate-to-high). Many HTN patients qualify for a statin separately, and the lipid panel is the only way to find out. Reveals metabolic syndrome (HTN + low HDL + high TG + central obesity + glucose intolerance), which warrants aggressive lifestyle and comorbidity treatment beyond just BP control. |
| HbA1c or fasting glucose | Screen for diabetes (compelling indication) + flag prediabetes / metabolic syndrome | A1c ≥ 6.5% = diabetes: tightens BP target to < 130/80 (ADA 2024), makes ACEi/ARB the preferred class if any albuminuria (UACR ≥ 30), and adds SGLT2i as a compelling indication for cardio-renal protection regardless of A1c. DM + albuminuric CKD: stack ACEi/ARB + SGLT2i + finerenone (FIDELIO-DKD / FIGARO-DKD). A1c 5.7-6.4% = prediabetes: nearly doubles 10-year ASCVD risk; aggressive lifestyle intervention with weight loss, DASH, exercise. Fasting glucose > 250 in an undiagnosed patient: assume long-standing DM with possible silent microvascular damage; lower threshold for ACEi/ARB and screen for retinopathy/nephropathy. Watch for hypoglycemia masking on BBs, especially atenolol, in insulin-treated diabetics. |
| TSH | Screen for a reversible secondary HTN cause | Hyperthyroidism (TSH < 0.1): causes systolic HTN with wide pulse pressure from increased CO. ~10-15% develop AFib. Often presents with palpitations, weight loss, tremor. Treat the thyroid first with methimazole (PTU in first trimester or thyroid storm) plus a BB (propranolol blocks T4→T3 conversion at high doses) for adrenergic symptoms. BP usually normalizes. Hypothyroidism (TSH > 10): causes diastolic HTN from peripheral vasoconstriction and reduced CO. Levothyroxine replacement normalizes BP within 6-8 weeks; recheck BP before adding antihypertensives. Subclinical hypothyroidism (TSH 4.5-10): contribution to HTN is debated; treatment for HTN benefit alone is unproven, but treat if TSH > 10, pregnancy, or symptoms. |
| Urine albumin/creatinine ratio (UACR) | Detect end-organ damage + identify compelling indication for ACEi/ARB | UACR < 30 mg/g: normal. No specific drug-class shift from this lab alone. UACR 30-300 (microalbuminuria): early hypertensive or diabetic nephropathy. Strong indication for ACEi or ARB even in stage 1 HTN (renal-protective per AASK 2002). Tightens BP target to < 130/80. UACR > 300 (macroalbuminuria): overt nephropathy. Add SGLT2i (DAPA-CKD 2020), goal BP < 130/80, possibly < 120/80 if tolerated. UACR > 3000 (nephrotic-range): workup for primary glomerular disease (FSGS, membranous, MPGN), consider renal biopsy. New UACR > 30 in an older patient without DM: think early hypertensive nephropathy and tighten BP target before drugs would otherwise be indicated. |
| ECG | Detect cardiac end-organ damage + screen for silent MI / arrhythmia | LVH (Sokolow-Lyon: S in V1 + R in V5 or V6 ≥ 35 mm; Cornell: S in V3 + R in aVL > 28 mm men / 20 mm women) = target-organ damage. Tightens BP target and shifts drug choice away from BBs toward ARB or ACEi per LIFE, 2002. Q waves or R-wave loss: prior silent MI = compelling indication for BB + ACEi. LBBB: think underlying cardiomyopathy → get an echo; if EF ≤ 35% with QRS ≥ 150, CRT candidate. Left atrial enlargement (P-wave > 120 ms or biphasic in V1): correlates with diastolic dysfunction and predicts AFib. New AFib on screening ECG changes management dramatically -anticoagulation if CHA₂DS₂-VASc ≥ 2, plus rate control. ST/T-wave changes: ischemia workup before tightening BP target (could be active angina). |
| Echocardiogram | Confirm structural cardiac end-organ damage (selective use) | Not routine for every HTN patient. Order when: ECG suggests LVH, exertional dyspnea or HFpEF symptoms, atypical features, severe HTN in a young patient, or murmur on exam. Echo-confirmed LVH (LV mass index > 115 g/m² men / > 95 g/m² women): confirms target-organ damage even when ECG is equivocal -tightens BP target and prefers ARB/ACEi over BB. Diastolic dysfunction (E/e′ > 14, LA volume index > 34 mL/m²): HFpEF is evolving -intensify BP control and add SGLT2i (EMPEROR-Preserved, DELIVER). Reduced EF < 50%: de novo HFrEF discovered -pivots management to the four GDMT pillars. Aortic root dilation in a tall, thin young patient: think Marfan; refer for genetic counseling and BB to reduce dP/dt. Aortic coarctation may explain unexpected HTN with arm-leg BP differential. |
Pattern: every initial lab answers one of four questions. (1) End-organ damage already present? (UACR, ECG, echo). (2) Reversible secondary cause? (BMP K⁺, TSH). (3) Compelling indication that drives drug choice? (A1c, UACR, BMP). (4) Drug-safety baseline? (BMP for Cr / K⁺ before RAAS or thiazide). One lab can answer multiple.
When to Screen for Secondary Causes
- Resistant HTN (uncontrolled on 3 drugs including a diuretic at maximally tolerated doses)
- Onset before age 30 or sudden new HTN after 65
- Severe HTN at presentation (≥ 180/120) without prior diagnosis
- Abrupt loss of control in previously stable HTN
- Hypokalemia (especially unprovoked) or hypertensive end-organ damage out of proportion to severity
- Episodic HTN with palpitations, headache, sweating (think pheochromocytoma)
- Daytime sleepiness, snoring, witnessed apnea (think OSA)
- Abdominal bruit, flash pulmonary edema, AKI on ACEi/ARB (think renovascular disease)
🚨 Management
▶ How to Escalate HTN Therapy, Step by Step (tap to expand)
Scope: uncomplicated essential HTN in adults. If a compelling indication is present (HFrEF, CKD with albuminuria, post-MI, DM, AF, pregnancy), drug choice is driven by the comorbidity (see Compelling Indications table). At every step, reinforce lifestyle (DASH + sodium < 1.5-2 g/day + weight loss + exercise stacks to a 20+ mmHg SBP drop, comparable to two-drug therapy).
Step 1: Confirm diagnosis before any drug
| Check | What | Why |
|---|---|---|
| Out-of-office BP | Home BP monitoring (HBPM) for 7 days, or 24-hour ambulatory BP (ABPM) | ~20% of "stage 1" office HTN is white-coat (normal home/ABPM, no drug needed) and ~10-15% of "normal" office BP is masked HTN (high home/ABPM, treat aggressively). Treating a number rather than a phenotype leads to hypotension, falls, and missed disease. |
| Correct technique | Seated 5 min, no caffeine/exercise 30 min prior, arm at heart level, appropriate cuff size, 2 readings averaged | Cuff too small adds ~10 mmHg; arm below heart adds ~5 mmHg. Bad technique fakes resistant HTN. |
| Baseline workup | BMP, lipids, A1c, TSH, urine albumin/Cr, ECG; 10-yr ASCVD risk | Identifies end-organ damage (LVH, CKD, albuminuria) and secondary-HTN clues. ASCVD risk drives the Stage 1 decision (treat at lower threshold if risk ≥ 10%). |
Step 2: Initiate based on stage and risk
| BP Stage | What to Do | Why |
|---|---|---|
| Normal/Elevated (< 130/80, or 120-129/< 80) | Lifestyle only. Reassess in 3-6 months. | No mortality benefit from drugs in this range. Capture early via lifestyle. |
| Stage 1 (130-139/80-89) | Lifestyle for 3-6 months; add monotherapy if 10-yr ASCVD risk ≥ 10%, established ASCVD, DM, CKD, or HF | SPRINT showed CV benefit of intensive control in high-risk patients. In low-risk Stage 1, lifestyle alone is enough. |
| Stage 2 (≥ 140/90, or > 20/10 above target) | Start dual therapy upfront, ideally as a single-pill combination | Monotherapy rarely closes a > 20/10 gap; needing 2-3 visits to get there wastes time and erodes adherence. ACCOMPLISH (2008): ACEi + amlodipine beat ACEi + HCTZ by 20% on MACE in high-risk patients. Single-pill combos improve adherence ~30%. |
First-line drug picks (no compelling indication):
- Non-Black: any of thiazide (chlorthalidone preferred), ACEi/ARB, or dihydropyridine CCB (amlodipine). ALLHAT showed all three are equivalent at population level.
- Black patient: thiazide or CCB first (ALLHAT: ACEi monotherapy is less effective at lowering BP and reduces stroke less). Add ACEi/ARB if CKD with albuminuria, DM, or HFrEF.
- Preferred dual combo: ACEi/ARB + amlodipine (ACCOMPLISH).
Step 3: Recheck and titrate at 2-4 weeks
Recheck BP and BMP at 2-4 weeks after starting or uptitrating. Catches thiazide-induced hypokalemia/hyponatremia/hyperuricemia and RAAS-induced hyperkalemia/Cr bump while they're still reversible. A Cr rise ≤ 30% on ACEi/ARB is expected and acceptable; only stop if rise > 30% or K+ > 5.5. Then titrate each agent to max tolerated before adding the next.
Step 4: Add the third agent
The classic 3-drug combo is ACEi/ARB + CCB + thiazide ("A + C + D"). Whichever class you didn't use in steps 2-3 is the third. If already on ACEi + CCB, add chlorthalidone. If on ACEi + thiazide, add amlodipine. This combination handles ~85-90% of HTN. Re-confirm out-of-office BP at this point, white-coat unmasking is common as the office number drops.
Step 5: If still uncontrolled on 3 drugs → resistant HTN workup
| Step | What | Why |
|---|---|---|
| Confirm true resistance | 3 agents at max-tolerated doses, one being a diuretic, ABPM or HBPM confirms elevated | ~30-50% of "resistant" cases are pseudo-resistance: non-adherence (most common, check pill counts and refill data), white-coat effect, bad measurement technique, or undertreated dose. Get this right before secondary workup. |
| Switch HCTZ → chlorthalidone if not already | Chlorthalidone 12.5-25 mg daily | Longer half-life (40-60h vs 6-15h) and better 24h BP control; many patients labeled "resistant" on HCTZ become controlled on equipotent chlorthalidone. |
| Add 4th agent: spironolactone | 12.5-25 mg daily (watch K+) | PATHWAY-2 (2015) showed spironolactone reduced home SBP an additional 8-10 mmHg, beating bisoprolol or doxazosin. First-line 4th agent per 2017 ACC/AHA. |
| Screen secondary HTN | Renin/aldosterone ratio, plasma metanephrines, renal artery duplex, sleep study, TSH, 24-hr urine cortisol | ~10-20% of resistant HTN has a secondary cause. Highest yield: primary aldosteronism (most common surgically curable cause; check ARR), OSA, renal artery stenosis, pheo, thyroid disease, Cushing. |
| Refer to HTN specialist | Persistent uncontrolled on 4+ agents | Consider renal denervation (SPYRAL HTN-ON MED, 2018+; FDA-approved 2023) or device-based therapies. Adherence-focused programs (directly observed therapy) can also resolve a substantial fraction. |
Shortcuts that override the ladder
| Scenario | Do This | Why |
|---|---|---|
| HFrEF | Use the 4 pillars (ARNI + BB + MRA + SGLT2i); these double as antihypertensives | HFrEF mortality drugs lower BP and reduce HF events. Don't add a separate "BP regimen" if GDMT already covers it. |
| CKD with albuminuria | ACEi or ARB first-line, regardless of race; add SGLT2i and finerenone (FIDELIO-DKD, FIGARO-DKD) | AASK: ACEi slows CKD progression in Black patients even though it lowers BP less. Renal benefit drives the choice. |
| Post-MI | BB + ACEi/ARB first-line | Both reduce post-MI mortality independent of BP (SAVE, 1992, AIRE, 1993). Build the BP regimen around these. |
| Stable CAD / established vascular disease (high CV risk) | ACEi (e.g., ramipril) for vascular protection, even at goal BP | HOPE, 2000: ramipril cut CV events ~22% beyond its small BP effect, launching ACEi as vascular protection independent of BP lowering. |
| DM with albuminuria | ACEi or ARB + SGLT2i | RAAS-blockade is renoprotective at any BP if albuminuria is present. |
| BPH | Add alpha-blocker (terazosin, doxazosin) as add-on, NOT monotherapy | Treats both. ALLHAT showed alpha-blocker monotherapy was inferior on CV outcomes. |
| Pregnancy | Labetalol, nifedipine, or methyldopa; treat at threshold ≥ 140/90 (CHAP 2022) | Avoid ACEi/ARB/ARNI/MRA/renin inhibitors, teratogenic (2nd-3rd trimester especially: renal dysgenesis, oligohydramnios). |
| Hyperkalemia (K+ > 5.5) on RAAS or MRA | Try patiromer or sodium zirconium cyclosilicate (SZC) before stopping RAAS or MRA | Mortality benefit of RAAS-blockade and MRA is lost on discontinuation. K+ binders preserve the regimen (DIAMOND, 2022). |
| AKI with Cr rise > 30% after ACEi/ARB start | Hold RAAS-blockade and screen for bilateral renal artery stenosis (renal duplex, MRA) | RAS unmasks itself when ACEi/ARB drops perfusion pressure to the post-stenotic kidney. Don't just reflexively stop and move on. |
| Gout / hyperuricemia | Prefer losartan (mildly uricosuric) or CCB; avoid thiazide if possible | Thiazides raise uric acid and trigger flares. If a thiazide is needed for BP, prophylax with allopurinol. |
| Hypertensive urgency (BP > 180/120, asymptomatic) | Restart held home meds, oral agent (clonidine, captopril, labetalol). Outpatient follow-up < 1 week. Do NOT lower > 25% in 24 hours. | Rapid lowering risks watershed stroke and MI. Numbers without end-organ damage are urgency, not emergency. |
| Hypertensive emergency (end-organ damage) | IV nicardipine, labetalol, clevidipine; lower MAP 25% in first hour, then to 160/100 over 2-6 hours. See HTN Emergency | End-organ damage (encephalopathy, MI, dissection, AKI, pulmonary edema) requires controlled IV lowering on telemetry. |
▶ BP Targets by Population (tap to expand)
| Population | Target | Evidence |
|---|---|---|
| General adult, high CV risk | < 130/80 | SPRINT, 2015 (intensive < 120 SBP reduced MACE 25%, mortality 27%; ACC/AHA adopted < 130/80 as practical target). Earlier, HOT, 1998 established DBP < 90 as the baseline target and < 80 in DM. |
| Diabetes | < 130/80 | ADA 2024, ACC/AHA 2017. ACCORD-BP, 2010: intensive < 120 SBP did NOT beat < 140 for the primary CV composite in DM and caused more AEs, driving the compromise to < 130/80. |
| CKD (any stage) | < 130/80 | KDIGO 2024. Even tighter (< 120/80) if proteinuric. |
| Post-stroke / secondary prevention | < 130/80 | PROGRESS, 2001: perindopril ± indapamide reduced recurrent stroke 28% regardless of baseline BP. SPS3, 2013 (lacunar stroke) supported the tighter target. |
| Older adult (≥ 65), non-frail | < 130/80 if tolerated | HYVET, 2008 showed treatment benefit even in patients ≥ 80. SPRINT included older adults with benefit. STEP, 2021 reproduced SPRINT-like benefit in elderly. |
| Older adult, frail / multiple comorbidities | < 140/90 reasonable | Avoid orthostatic falls. Target individualized. |
| Pregnancy | < 140/90 (treat at ≥ 140/90) | CHAP, 2022. Labetalol, nifedipine, methyldopa are first-line. Avoid ACEi/ARB (teratogenic, especially 2nd-3rd trimester). |
SPRINT vs ACCORD-BP: why the intensive target splits on diabetes
Same intensive target (SBP < 120), opposite results, divided by diabetes status. This trial pair is the reason the guideline target settled at < 130/80 rather than < 120.
- SPRINT, 2015 (nondiabetic, N = 9,361): intensive SBP < 120 vs < 140 reduced the primary CV composite 25% and all-cause mortality 27%. Stopped early for benefit. (Excluded diabetes and prior stroke.)
- ACCORD-BP, 2010 (type 2 diabetes, N = 4,733): intensive SBP < 120 did NOT reduce the primary CV composite or mortality. Only stroke fell (~41%), while serious treatment-related adverse events rose (hypotension, syncope, hyperkalemia, renal effects).
Bedside takeaway: push toward SBP < 120 only in high-risk nondiabetic patients who tolerate it. In diabetes, settle at < 130/80, because the extra push to < 120 buys some stroke reduction at the cost of more harm and no mortality or composite benefit.
Lifestyle Interventions (always first or concurrent)
| Intervention | Approximate SBP / DBP Effect | Note |
|---|---|---|
| DASH diet | ↓ 11 / 3 mmHg | DASH, 1997: high in fruits, vegetables, low-fat dairy; reduced saturated fat. DASH-Sodium, 2001 showed sodium restriction is additive. |
| Sodium restriction (< 1.5-2 g/day) | ↓ 5 / 3 mmHg | Greater effect in Black patients, older adults, salt-sensitive HTN. |
| Weight loss | ↓ ~1 / 1 mmHg per kg | Sustained effect. Most impactful in obese patients. |
| Aerobic exercise | ↓ 4 / 3 mmHg | ≥ 90-150 min/week moderate intensity. |
| Alcohol reduction | ↓ 4 / 3 mmHg | Limit to ≤ 2 drinks/day men, ≤ 1 drink/day women. |
| Smoking cessation | Variable acute, large CV mortality benefit | Doesn't lower chronic BP much, but huge CV impact. |
Stacking lifestyle changes is additive. A patient who adopts DASH plus sodium restriction plus weight loss plus exercise can achieve a 20+ mmHg SBP drop, comparable to two-drug therapy.
First-line Drug Selection
Initiate two-drug combination therapy if BP is > 20/10 above target. Monotherapy is rarely adequate at stage 2. Single-pill combinations improve adherence dramatically. When choosing a combination, ACCOMPLISH, 2008 showed ACEi + amlodipine outperformed ACEi + HCTZ for CV outcomes (20% relative risk reduction in MACE) in high-risk patients.
| Patient | First-line Choice | Why |
|---|---|---|
| General non-Black, no compelling indication | Thiazide (chlorthalidone preferred) OR ACEi/ARB OR dihydropyridine CCB (amlodipine) | All three classes have similar BP-lowering and CV outcome benefit at population level. |
| Black patient (no compelling indication) | Thiazide OR CCB (not ACEi/ARB monotherapy) | ALLHAT, 2002: ACEi monotherapy is less effective at lowering BP in Black patients. Add an ACEi/ARB if concomitant CKD, DM with albuminuria, or HFrEF. |
| Compelling indication present | See compelling indications table below | Drug selection driven by comorbidity, not just BP. |
Compelling Indications (let comorbidity drive drug choice)
| Comorbidity | Preferred Drug Class(es) | Avoid |
|---|---|---|
| HFrEF | ARNI (or ACEi/ARB) + evidence-based BB (carvedilol, metoprolol succinate, bisoprolol) + MRA + SGLT2i. See Heart Failure (Chronic). | Non-DHP CCBs (diltiazem, verapamil), most BBs other than the three evidence-based ones. |
| CKD with proteinuria | ACEi or ARB (mortality and renal-protective). Add SGLT2i. AASK, 2002: ACEi slowed renal disease progression in Black patients with hypertensive CKD. | Combining ACEi + ARB (no benefit, more AKI/hyperK; ONTARGET, 2008). |
| Post-MI | BB + ACEi/ARB (both reduce mortality post-MI). HOPE, 2000: ACEi reduced CV death/MI/stroke 22% in high-risk patients, beyond BP effect alone. | Non-DHP CCBs in HFrEF post-MI. |
| DM | ACEi or ARB if albuminuria. SGLT2i for renal/CV protection. Otherwise any first-line is reasonable. | , |
| Atrial fibrillation needing rate control | BB or non-DHP CCB. | Non-DHP CCBs in HFrEF. |
| Stable angina | BB first; CCB if BB contraindicated or insufficient. | , |
| HTN with gout / hyperuricemia | Losartan (uricosuric) or CCB. Avoid thiazide if possible. | Thiazides (raise uric acid). |
| BPH | Alpha-blocker (terazosin, doxazosin) as add-on. Treats both. | Alpha-blocker monotherapy (ALLHAT showed inferior outcomes). |
| Pregnancy | Labetalol, nifedipine, methyldopa. | ACEi, ARB, ARNI, MRA, direct renin inhibitors (teratogenic). |
Follow-up Cadence
- After starting or changing therapy: recheck BP and BMP in 2-4 weeks.
- Stable on regimen: visit q3-6 months; BMP q6-12 months -monitor for thiazide effects (hypokalemia, hyponatremia, hyperuricemia, mild glucose intolerance) and RAAS-inhibitor effects (hyperkalemia, Cr bump). Recheck BMP within 1-2 weeks any time you start or uptitrate a thiazide, ACEi/ARB, ARNI, or MRA -that's the highest-yield window for catching these.
- Home BP monitoring at every visit. Target: home average matches office target. If home is consistently lower than office → suspect white-coat effect.
- Non-adherence is the most common reason for "resistance." Always check pill counts, refill data, and consider direct-observed dosing or single-pill combinations before escalating.
- Time-of-day dosing doesn't matter. TIME, 2022 showed evening dosing does NOT reduce CV events vs morning. Pick the time the patient is most likely to remember.
💊 Medications
First-line Classes
| Drug | Starting → Target Dose | Key Notes |
|---|---|---|
| Chlorthalidone PREFERRED THIAZIDE | 12.5-25 mg PO daily (max 25-50) | Preferred over HCTZ -longer half-life (40-60h vs 6-15h), better 24h BP control, may reduce CV events more. Watch hypokalemia, hyperuricemia, hyponatremia. Outcome data: ALLHAT, 2002 (chlorthalidone matched amlodipine/lisinopril for CHD and was superior for preventing heart failure; established thiazide as first-line); SHEP, 1991 (cut stroke 36% in elderly isolated systolic HTN). |
| Hydrochlorothiazide (HCTZ) ALTERNATIVE | 25-50 mg PO daily | Cheaper, more familiar, but weaker 24h coverage. Use chlorthalidone if available. Note: the landmark outcome trials (ALLHAT, 2002, SHEP, 1991) used chlorthalidone, not HCTZ -HCTZ's CV-outcome evidence is weaker. |
| Amlodipine (Norvasc) DHP CCB | 2.5-5 → 10 mg PO daily | Excellent for systolic HTN in elderly. Pedal edema common (dose-dependent, not from fluid retention). Safe in HFrEF. ALLHAT, 2002 (CV-equivalent to thiazide); ACCOMPLISH, 2008 (ACEi + amlodipine beat ACEi + HCTZ by 20% on MACE; the preferred dual combo). Check the statin before you prescribe it: amlodipine inhibits CYP3A4 and caps simvastatin at 20 mg/day (FDA label) because simvastatin exposure rises ~1.8x, raising myopathy and rhabdomyolysis risk. Since 20 mg is only moderate-intensity (~30% LDL drop), a patient who needs high-intensity therapy should be switched to atorvastatin or rosuvastatin rather than dose-capped -neither carries an amlodipine dose cap. Amlodipine is the least restrictive CCB here: the non-DHPs are stricter still, capping simvastatin at 10 mg (diltiazem, verapamil). |
| Lisinopril (Zestril) ACEi | 10 → 40 mg PO daily | Cough (~10%, persistent) and angioedema (rare but serious). Hyperkalemia. Avoid in pregnancy. ALLHAT, 2002 (equivalent overall, but weaker BP-lowering and stroke protection as monotherapy in Black patients). |
| Losartan (Cozaar) ARB | 50 → 100 mg PO daily | No cough. Uniquely uricosuric among ARBs, by inhibiting URAT1 in the proximal tubule, so it is the ARB of choice in HTN with gout or hyperuricemia and a useful counterweight to a thiazide, which raises urate. Hyperkalemia. Avoid in pregnancy. LIFE, 2002 (beat atenolol on stroke in LVH despite similar BP). ⚠ Two limits, and both explain why patients "fail" losartan. It is the shortest-acting ARB, so control measurably fades before 24 h and morning readings run high on once-daily dosing. And it is capped at 100 mg, a lower ceiling than the rest of the class, so once you are there you are out of room. Before adding a second drug, consider BID dosing or switching to a longer-acting, higher-ceiling ARB, which is often the cheaper fix. |
| Valsartan (Diovan) ARB | 80 → 320 mg PO daily | At least as commonly used as losartan, and the one to know because it is the ARB inside sacubitril/valsartan (Entresto). Titrate properly: the target is 320 mg, and much of its reputation for being weak comes from being left at 80 mg. VALUE, 2004 found no difference versus amlodipine on the primary cardiac endpoint, though amlodipine dropped BP faster early, while valsartan produced less new-onset diabetes and fewer heart failure hospitalizations. |
| Other ARBs PICK BY COMORBIDITY | Candesartan 8 → 32 mg Irbesartan 150 → 300 mg Telmisartan 40 → 80 mg Olmesartan 20 → 40 mg | The class is not interchangeable, and the differences are worth knowing. ⚠ Do not confuse potency per milligram with how much blood pressure you can actually get. Per mg the order is candesartan > telmisartan ≈ losartan > irbesartan ≈ valsartan, but that ranking does not predict the clinical result, because the dose ceilings differ threefold. Losartan stops at 100 mg while valsartan goes to 320 mg, so at real maximum doses valsartan lowers BP MORE than losartan (−15.3/−11.3 mmHg for valsartan 160 mg vs −12.0/−9.4 mmHg for losartan 100 mg) Nixon meta-analysis, 2009. For 24-hour control, candesartan, telmisartan and irbesartan hold across the full dosing interval where losartan does not. Across network meta-analyses olmesartan ranks highest for office BP reduction and candesartan for 24-hour ambulatory systolic. Pick by the comorbidity: irbesartan for type 2 diabetic nephropathy, which cut the renal composite 20% vs placebo and 23% vs amlodipine IDNT, 2001; candesartan where heart failure coexists, with a 12% reduction in all-cause mortality CHARM, 2003; losartan where gout coexists. ⚠ Olmesartan carries a rare sprue-like enteropathy with chronic diarrhea and weight loss that resolves on stopping, and is worth remembering before working such a patient up for celiac disease. |
| ACE inhibitor or ARB? EQUIVALENT ON BP | Pick one. Never both. | Neither is stronger. Head to head they lower blood pressure by the same amount, and in the largest comparison telmisartan was non-inferior to ramipril for major cardiovascular events with a trivial 0.9/0.6 mmHg BP difference ONTARGET, 2008. So choose on side effects, not on potency. The whole difference is bradykinin: ACE inhibitors block its breakdown, which produces the cough in roughly 10% and the angioedema, and ARBs do neither because they act at the receptor instead. Start with either; switch to an ARB for cough. Both cause hyperkalemia, both bump creatinine, and both are contraindicated in pregnancy. ⚠ Never combine them: in the same trial dual blockade added no benefit at all while significantly increasing hypotension, syncope, renal dysfunction and hyperkalemia. A creatinine rise up to 30% after starting either is expected and is not a reason to stop, since it reflects the intended drop in intraglomerular pressure; a larger rise should prompt a look for renal artery stenosis. |
| Metoprolol succinate (Toprol-XL) BB - COMPELLING ONLY | 25 → 200 mg PO daily | Not first-line for uncomplicated HTN (less stroke reduction than thiazide/CCB/ACEi). Use for HFrEF, post-MI, AFib rate control. MERIT-HF, 1999 (HFrEF mortality benefit). |
| Carvedilol (Coreg) BB - HFrEF | 3.125 BID → 25 BID | Alpha + beta blockade. HFrEF preferred BB. COPERNICUS, 2001 (mortality ↓35% in severe HFrEF); COMET, 2003 (beat metoprolol tartrate on mortality). |
Olmesartan pearl, sprue-like enteropathy. Olmesartan (Benicar; also in Azor, Benicar HCT, Tribenzor) can cause a distinctive sprue-like enteropathy: severe chronic diarrhea, weight loss, and small-bowel villous atrophy that mimics celiac disease. The catch: celiac serologies are negative and it does NOT respond to a gluten-free diet, and onset can be months to years after starting. It resolves on stopping the drug (and recurs on rechallenge). FDA warning 2013 (Mayo Clinic case series). Why it matters: in any patient on olmesartan with unexplained chronic diarrhea and seronegative villous atrophy, stop the drug before labeling it refractory celiac, that single step is often curative.
Add-on / Combination Agents
| Drug | Dose | Role |
|---|---|---|
| Spironolactone (Aldactone) | 12.5-50 mg daily | Fourth-line for resistant HTN (PATHWAY-2, 2015). Also for primary aldosteronism. Watch hyperkalemia, gynecomastia (~10%, switch to eplerenone if bothersome). |
| Hydralazine (Apresoline) | 10-50 mg PO TID-QID (start 10 mg QID) | Direct arteriolar vasodilator. Useful in pregnancy and as add-on. Reflex tachycardia (pair with BB), drug-induced lupus at > 200 mg/day or in slow acetylators. |
| Clonidine (Catapres) | PO: 0.1 mg BID, titrate to max 0.6 mg/day. Patch: 0.1-0.3 mg/24h, change weekly. | Central alpha-2 agonist. Avoid as monotherapy -severe rebound HTN if missed doses. Patch helpful for adherence-limited resistant HTN. |
| Doxazosin (Cardura) | 1 → 16 mg daily (start 1 mg qhs) | Alpha-blocker. Add-on for resistant HTN, especially with BPH. Monotherapy inferior (ALLHAT, 2002). Watch first-dose orthostatic syncope -dose at bedtime. |
| Diltiazem ER (Cardizem CD, Tiazac) | 180-360 mg PO daily | Non-DHP CCB. Useful for HTN + AFib needing rate control. Avoid in HFrEF (negative inotropy). |
| Verapamil ER (Calan SR, Verelan) | 180-480 mg PO daily | Non-DHP CCB. Same role as diltiazem; more constipation. Avoid in HFrEF. |
▶ Single-Pill Combinations - Brand Names & Strengths (tap to expand)
Single-pill combinations cut pill burden and dramatically improve adherence. Most guidelines now recommend starting Stage 2 HTN with a single-pill dual combination rather than two separate pills.
| Combination | Brand Name | Available Strengths (mg) |
|---|---|---|
| ACEi/ARB + Amlodipine (preferred combo per ACCOMPLISH) | ||
| Olmesartan + amlodipine | Azor | 20/5, 40/5, 40/10 |
| Valsartan + amlodipine | Exforge | 5/160, 10/160, 5/320, 10/320 |
| Benazepril + amlodipine | Lotrel | 10/2.5, 10/5, 20/5, 20/10, 40/5, 40/10 |
| Telmisartan + amlodipine | Twynsta | 40/5, 40/10, 80/5, 80/10 |
| Perindopril + amlodipine | Prestalia | 3.5/2.5, 7/5, 14/10 |
| ACEi/ARB + Thiazide | ||
| Lisinopril + HCTZ | Zestoretic, Prinzide | 10/12.5, 20/12.5, 20/25 |
| Losartan + HCTZ | Hyzaar | 50/12.5, 100/12.5, 100/25 |
| Valsartan + HCTZ | Diovan HCT | 80/12.5, 160/12.5, 160/25, 320/12.5, 320/25 |
| Olmesartan + HCTZ | Benicar HCT | 20/12.5, 40/12.5, 40/25 |
| Telmisartan + HCTZ | Micardis HCT | 40/12.5, 80/12.5, 80/25 |
| Irbesartan + HCTZ | Avalide | 150/12.5, 300/12.5, 300/25 |
| Enalapril + HCTZ | Vaseretic | 5/12.5, 10/25 |
| Triple Combinations (ARB + Amlodipine + Thiazide) | ||
| Olmesartan + amlodipine + HCTZ | Tribenzor | 20/5/12.5, 40/5/12.5, 40/5/25, 40/10/12.5, 40/10/25 |
| Valsartan + amlodipine + HCTZ | Exforge HCT | 5/160/12.5, 10/160/12.5, 5/160/25, 10/160/25, 10/320/25 |
| ARB + Neprilysin Inhibitor (HFrEF, not first-line HTN) | ||
| Sacubitril + valsartan | Entresto | 24/26, 49/51, 97/103 BID |
Don't combine ACEi + ARB. No CV benefit but significantly more hyperkalemia, AKI, and hypotension (ONTARGET, 2008). Same applies to ACEi/ARB + direct renin inhibitor (aliskiren).
▶ Why Beta-Blockers Aren't First-Line for Uncomplicated HTN (tap to expand)
BBs lower brachial cuff BP just as well as thiazides, CCBs, and ACEi/ARB at equivalent doses, but they consistently underperform for stroke and CV outcomes. Two converging mechanisms explain this gap.
Mechanism 1: BBs don't lower CENTRAL aortic pressure as well as they lower brachial pressure
The pressure your heart, brain, and kidneys actually see is the aortic root pressure, not the brachial cuff pressure. The two are usually close, but not always:
- The arterial pulse generates a forward wave that travels distally and a reflected wave that bounces back from peripheral arteries.
- In young, compliant arteries, the reflected wave returns in diastole -augmenting coronary perfusion (good).
- In stiff aging arteries, pulse wave velocity is faster and the reflected wave returns earlier, in late systole -augmenting central aortic systolic pressure (bad).
- BBs slow heart rate → longer ejection time → reflected wave returns even earlier in systole → more central pressure augmentation. The brachial cuff misses this because the reflection adds less to peripheral readings.
- CCBs and ACEi/ARB vasodilate peripheral arteries → reduce wave reflection → drop central pressure more than BBs do at the same brachial reading.
CAFE substudy of ASCOT, 2006: amlodipine ± perindopril vs atenolol ± thiazide produced near-identical brachial BP, but central aortic pressure was 4-5 mmHg lower on the CCB/ACEi arm. This central pressure gap explained the CV outcome benefit seen in the parent ASCOT-BPLA, 2005 trial.
Mechanism 2: Other BB disadvantages in uncomplicated HTN
- Worse stroke prevention at equipotent BP (LIFE 2002, MRC 1992, ASCOT 2005 all consistent).
- Adverse metabolic profile -atenolol increases new-onset diabetes (especially when combined with thiazide), promotes weight gain, worsens lipid profile.
- Bradycardia and fatigue reduce adherence in working-age patients.
- Withdrawal rebound HTN if doses missed; abrupt discontinuation is dangerous.
- Atenolol is the worst offender -most of the negative trials used atenolol. Vasodilating BBs (carvedilol, nebivolol, labetalol) have a more favorable hemodynamic profile because they reduce peripheral vascular resistance and may not worsen central pressure as much.
When BBs ARE Indicated (compelling indications)
| Indication | Preferred BB(s) | Why |
|---|---|---|
| HFrEF | Carvedilol, metoprolol succinate, bisoprolol | Mortality benefit, one of the four GDMT pillars. Only these three have HFrEF trial evidence. |
| Post-MI (first 1-3 years) | Metoprolol succinate, carvedilol, bisoprolol | Mortality reduction in the early post-MI window. Continue at least 1 year, often longer with reduced EF. |
| Atrial fibrillation needing rate control | Metoprolol, atenolol, bisoprolol, carvedilol | Slows AV nodal conduction. Drug selection by HF status. Diltiazem/verapamil are alternatives if no HFrEF. |
| Stable angina | Metoprolol, atenolol, bisoprolol, carvedilol | Reduces myocardial O₂ demand (HR, contractility). First-line antianginal. |
| Aortic dissection (acute) | IV esmolol or labetalol | Lower HR BEFORE BP -reducing dP/dt minimizes wall shear stress propagating the dissection. |
| Thyrotoxicosis / thyroid storm | Propranolol | Blocks adrenergic excess; propranolol also blocks T4→T3 conversion at high doses. |
| Hypertension in pregnancy | Labetalol | First-line in pregnancy (alpha + beta blockade). Methyldopa and nifedipine are alternatives. |
| Migraine prophylaxis with comorbid HTN | Propranolol, metoprolol | Well-validated for migraine prevention; treats both conditions. |
| Essential tremor with HTN | Propranolol | First-line for tremor. Dual indication. |
| Pheochromocytoma (after alpha block) | Any BB, after phenoxybenzamine | Never start BB before alpha block -unopposed alpha stimulation → hypertensive crisis. |
| Resistant HTN (4th/5th line) | Bisoprolol | PATHWAY-2 2015 showed spironolactone is preferred 4th drug, but bisoprolol is reasonable 5th if HR > 70 or as alternative when MRA is contraindicated. |
One-line takeaway: if your HTN patient has no compelling indication, a thiazide, CCB, or ACEi/ARB will protect them better than a beta-blocker -even though the cuff numbers look the same. The cuff lies; central aortic pressure tells the truth.
▶ Antihypertensives in CKD & AKI - What to Avoid & What to Use (tap to expand)
CKD changes the pharmacology of every antihypertensive class. Some accumulate (toxicity), some lose efficacy, some cause hyperkalemia, and some are actively renal-protective. Pick agents based on eGFR and compelling indications.
Atenolol is the classic CKD trap. ~50% renally excreted unchanged. Half-life extends from 6-9h (normal kidneys) to 16-30+ hours in advanced CKD. Accumulation causes symptomatic bradycardia, hypotension, fatigue, AV block, and hypoglycemia unawareness in diabetics. Dialyzable, so HD patients must be dosed post-dialysis. Switch to a hepatically cleared BB (metoprolol, carvedilol, labetalol) whenever possible.
Beta-blockers in CKD
| Drug | Clearance | CKD Action |
|---|---|---|
| Atenolol AVOID | ~50% renal | Avoid if possible. If needed: max 50 mg/day at eGFR 15-35, max 25 mg/day or QOD at eGFR < 15. Dose post-HD (dialyzable). |
| Nadolol AVOID | Renal | Very long half-life that extends further in CKD. Switch to a hepatic BB. |
| Sotalol AVOID | Renal | Renally cleared and QT-prolonging. Dangerous combination in CKD. If used for rhythm control, dose-adjust by CrCl with frequent QTc monitoring. |
| Bisoprolol ADJUST | ~50% renal / 50% hepatic | Mild adjustment. Start 2.5 mg at eGFR < 40. Still acceptable as an HFrEF GDMT pillar in CKD. |
| Metoprolol succinate / tartrate PREFERRED | Hepatic | No renal dose adjustment. Preferred BB in CKD when there's a compelling indication. |
| Carvedilol PREFERRED | Hepatic | No renal dose adjustment. HFrEF first-line, also useful for CKD with HF overlap. |
| Labetalol, propranolol, nebivolol PREFERRED | Hepatic | No renal adjustment. Labetalol is preferred in pregnancy with CKD. |
RAAS blockers (ACEi / ARB / ARNI / aliskiren)
| Drug | CKD Considerations | Action |
|---|---|---|
| ACEi (lisinopril, ramipril, enalapril) RENAL-PROTECTIVE | Renally cleared. Renal-protective in proteinuric CKD (AASK, 2002). Hyperkalemia and 10-30% Cr rise on initiation. | Preferred in CKD with albuminuria (UACR > 30). Mild dose adjustment for severe CKD. Hold if Cr rises > 30% from baseline or K⁺ > 5.5. The expected hemodynamic Cr bump (≤ 30%) is OK and reverses on stopping. |
| Fosinopril UNIQUE | The only ACEi cleared hepatically (the rest are renal). | No renal dose adjustment. Useful when other ACEi accumulate or patient is on multiple renally cleared drugs. |
| ARBs (losartan, valsartan, telmisartan, etc.) RENAL-PROTECTIVE | Same renal-protective and hyperK profile as ACEi. Most don't need major dose adjustment. | Same role as ACEi in CKD. Switch from ACEi if cough or angioedema. Don't combine with ACEi (ONTARGET, 2008: more AKI, hyperK, hypotension, no benefit). |
| Sacubitril/valsartan (Entresto, ARNI) CAUTION | Limited data at eGFR < 30. Same hyperK and hypotension concerns as ACEi/ARB. | Avoid initiation at eGFR < 30. If eGFR drops below 30 on therapy, individualize. |
| Aliskiren (direct renin inhibitor) AVOID | High AKI and hyperkalemia risk, especially when combined with ACEi or ARB. | Avoid in CKD. Never combine with ACEi/ARB. |
Diuretics in CKD
| Drug | CKD Considerations | Action |
|---|---|---|
| HCTZ, chlorthalidone LIMITED | Lose efficacy at eGFR < 30 (poor delivery to distal tubule). | Switch to loop diuretic at eGFR < 30. Metolazone is the only thiazide-like agent that retains effect at low GFR. |
| Metolazone CKD-FRIENDLY | Thiazide-like. Works at any GFR. Synergistic with loop diuretics. | Useful as add-on for diuretic resistance in CKD. Monitor K⁺, Mg, Na. |
| Loop diuretics (furosemide, torsemide, bumetanide) PREFERRED | Work at any GFR but often need higher doses as CKD advances. | First-line diuretic at eGFR < 30 for both volume and BP. Torsemide preferred for outpatient (better PO bioavailability). |
| MRA (spironolactone, eplerenone) HYPERK RISK | Hyperkalemia risk rises sharply as eGFR drops. | Avoid at eGFR < 30. Caution 30-60 with frequent K⁺ monitoring (3 days, 1 week, monthly). Consider K-binder (patiromer, sodium zirconium) before discontinuing in CKD/HF overlap where the MRA is providing mortality benefit. |
| Acetazolamide CAUTION | Renally cleared, can worsen metabolic acidosis (already common in CKD). | Avoid or reduce. Not typically used for HTN anyway. |
CCBs and other agents
| Drug Class | CKD Considerations | Action |
|---|---|---|
| Amlodipine, felodipine, nifedipine ER (DHP CCBs) PREFERRED | Hepatically cleared. | Safe at any eGFR. No dose adjustment. Excellent first-line in CKD HTN. |
| Diltiazem, verapamil (non-DHP CCBs) | Hepatically cleared. | Safe in CKD. Avoid in HFrEF (negative inotropy). |
| Doxazosin, terazosin (alpha-blockers) | Hepatically cleared. | Safe in CKD. Useful add-on with BPH coexistence. |
| Hydralazine CKD-FRIENDLY | Hepatically cleared. | No renal adjustment. Useful in resistant HTN with CKD when other classes are limited. |
| Clonidine ADJUST | Renally cleared, accumulates in CKD. | Reduce dose. Patch is preferred for steady levels and adherence (avoids the rebound HTN problem). |
| Methyldopa | Renally cleared. | Mild adjustment. Mostly used in pregnancy. |
| Minoxidil | Hepatically cleared, but causes fluid retention and reflex tachycardia. | Reserved for severe resistant HTN with CKD on dialysis. Pair with loop diuretic + BB. |
| NSAIDs NEVER | Drive AKI, blunt BP control, worsen HTN. Even short courses precipitate AKI in CKD. | Avoid in CKD always. Use acetaminophen for pain. |
AKI: Same Principles, More Urgent
AKI is a moving target. Atenolol's accumulation problem is worse in AKI than in stable CKD because you can't predict drug clearance as kidney function changes hour-to-hour, and AKI patients are usually hemodynamically labile (sepsis, post-op, volume shifts). The same logic applies to every renally cleared antihypertensive.
HTN drugs to HOLD when AKI develops on a hypertensive patient:
- ACEi / ARB / ARNI -dilate the efferent arteriole and drop GFR further. Especially harmful in pre-renal AKI or bilateral RAS. Hold until Cr is stable, then resume cautiously.
- Aliskiren -same problem as ACEi/ARB but worse. Always hold.
- NSAIDs -constrict the afferent arteriole, drive AKI directly. Always off in AKI, even short courses.
- Atenolol, nadolol, sotalol -accumulate unpredictably. Switch to a hepatic BB.
- Spironolactone, eplerenone -hyperkalemia risk skyrockets when GFR drops acutely. Hold.
- HCTZ / chlorthalidone -lose efficacy at low GFR anyway; switch to a loop if diuresis is needed.
- Oral clonidine -accumulates; switch to patch (steady release, less rebound risk if doses missed).
- Metformin (not HTN, but always check) -hold in any significant AKI to prevent lactic acidosis.
Safe to keep or start in AKI for HTN control:
- Amlodipine -hepatic, no adjustment, safe at any GFR.
- Hydralazine -hepatic, useful for resistant HTN in AKI when other classes are limited.
- Hepatic BBs -metoprolol, carvedilol, labetalol. Switch from atenolol if patient was on it.
- Loop diuretics if volume-overloaded; often need higher doses as AKI progresses.
- IV options for severe HTN in AKI: nicardipine (DHP CCB), labetalol (alpha+beta blocker), esmolol (ultrashort BB, t½ ~9 min, hepatic clearance, ideal when you want the option to bail quickly).
One-line rule: If renal clearance is impaired for any reason -chronic (CKD) or acute (AKI) -atenolol accumulates and gets you in trouble. AKI is actually riskier than stable CKD because the kidney function is a moving target.
CKD HTN cheat sheet:
- Proteinuria + CKD → ACEi or ARB first (renal-protective per AASK 2002).
- Add SGLT2i for any CKD patient with eGFR > 20 - mortality and renal-protective regardless of diabetes (DAPA-CKD 2020).
- Need a CCB → amlodipine, hepatically cleared and safe at any GFR.
- Need a diuretic at eGFR < 30 → loop (furosemide / torsemide). Add metolazone if resistance.
- Need a BB → metoprolol, carvedilol, or labetalol. Avoid atenolol, nadolol, sotalol.
- Resistant HTN in CKD → spironolactone IF eGFR > 30 and K⁺ < 5.0; otherwise hydralazine, clonidine patch, or minoxidil.
- Always: NSAIDs OFF, K⁺ monitored, expect Cr bump on RAAS initiation.
⚠️ Resistant HTN
Definition
Resistant HTN = BP above goal despite three drugs of different classes (one of which is a diuretic) at maximally tolerated doses, OR controlled BP requiring four or more drugs.
Step 1: Rule Out Pseudoresistance
- Non-adherence -the #1 reason. Check refill records, pill counts. Direct-observed therapy is gold standard. Single-pill combinations improve adherence.
- White-coat effect -confirm with home BP monitoring or ABPM.
- Inadequate dosing -is each agent at maximal tolerated dose? Is the diuretic chlorthalidone (preferred) or HCTZ?
- Wrong diuretic for renal function -loop diuretic is needed at eGFR < 30; thiazides lose efficacy (except metolazone).
- Drug or substance contributors -NSAIDs, oral contraceptives, decongestants (pseudoephedrine), cocaine/amphetamines, glucocorticoids, licorice (mineralocorticoid mimic), erythropoietin, calcineurin inhibitors.
Step 2: Screen for Secondary Causes
| Cause | Screening Test | Confirmatory |
|---|---|---|
| Primary aldosteronism (most common, ~5-13% of all HTN) | Morning aldosterone-to-renin ratio (ARR). ARR > 20-30 with aldosterone > 15 ng/dL. Hold MRA ≥ 4 weeks, ACEi/ARB/diuretics ≥ 2 weeks before testing. | Salt-loading test or saline suppression. Then adrenal vein sampling (gold standard) to localize unilateral vs bilateral. CT alone misses ~38% of unilateral disease. |
| Obstructive sleep apnea | STOP-BANG questionnaire. Witnessed apnea, snoring, daytime sleepiness, BMI > 35. | Polysomnography (in-lab) or home sleep apnea testing. Treat with CPAP -modest BP reduction (3-5 mmHg). |
| Renovascular disease (atherosclerotic in older adult; fibromuscular dysplasia in young woman) | Renal artery duplex, MRA, or CTA. Suspect with abdominal bruit, flash pulmonary edema, AKI on ACEi/ARB. | CTA or MRA. Angiography if intervention planned. Stenting only if > 70% stenosis with refractory HTN or recurrent HF (CORAL, 2014 was negative for routine stenting in atherosclerotic RAS). |
| CKD | BMP, UACR. Often both cause and consequence of HTN. | Renal US for size and obstruction. |
| Pheochromocytoma | Plasma free metanephrines OR 24-hour urine fractionated metanephrines. | CT/MRI adrenals. Do NOT biopsy -triggers catecholamine crisis. Alpha-block (phenoxybenzamine) BEFORE beta-block. |
| Cushing's syndrome | 24-hour urine free cortisol, late-night salivary cortisol, or low-dose dexamethasone suppression test. | If positive, ACTH-dependence assessment, then localize source. |
| Thyroid disease | TSH | Free T4 if abnormal. |
| Coarctation of aorta (young patient) | BP differential between arms and legs (legs lower). Radial-femoral pulse delay. | Echocardiogram, CTA aorta. |
Step 3: Add the Right Fourth Drug
PATHWAY-2, 2015: Spironolactone is the preferred fourth-line agent for resistant HTN. Outperformed bisoprolol and doxazosin for BP reduction in patients on optimized A+C+D (ACEi/ARB + amlodipine + chlorthalidone).
- Spironolactone 12.5-50 mg daily -fourth-line of choice. Watch K⁺ (especially with concomitant ACEi/ARB). Switch to eplerenone if gynecomastia.
- Alternatives if spironolactone contraindicated or intolerable: bisoprolol (resting HR > 70), doxazosin (BPH coexists), or clonidine.
- Renal denervation -SPYRAL HTN-ON MED, 2020 showed efficacy on top of optimized triple therapy (SBP ↓ 4-5 mmHg vs sham). FDA-approved (2023) for resistant HTN; modest overall benefit (~5-10 mmHg SBP reduction). Specialty referral.
📋 On Rounds
Pimp Questions
Why is chlorthalidone preferred over HCTZ?
Longer half-life (40-60h vs 6-15h for HCTZ) gives better 24-hour BP control, especially overnight. Multiple meta-analyses suggest greater CV event reduction at equipotent doses. Trade-off: higher rates of hypokalemia and hyponatremia, so monitor electrolytes more closely. Chlorthalidone 12.5-25 mg ≈ HCTZ 25-50 mg in BP-lowering effect.
Why isn't a beta-blocker first-line for uncomplicated HTN?
BBs lower BP but have weaker stroke reduction than thiazides, CCBs, or ACEi/ARB at equipotent BP-lowering. LIFE, 2002 (atenolol vs losartan in HTN with LVH) showed BBs underperformed for stroke prevention despite similar BP lowering. They're still first-line when there's a compelling indication (HFrEF, post-MI, AFib rate control), just not for HTN alone.
A 32-year-old woman has BP 168/104 with serum K⁺ 3.1. What's the diagnosis to consider?
Primary aldosteronism -unprovoked hypokalemia plus HTN should always trigger this consideration. It's the most common secondary cause (~5-13% of all HTN, often normokalemic). Workup: morning aldosterone-to-renin ratio (ARR), hold MR antagonists ≥ 4 weeks and ACEi/ARB/diuretics ≥ 2 weeks first. Confirm with salt-loading or saline suppression test, then adrenal vein sampling to localize.
What's the most common reason a patient appears to have resistant HTN?
Non-adherence -by far the #1 cause. Studies using directly-observed therapy or pill-counts show that 30-50% of "resistant" patients are simply not taking their medications. Other pseudoresistance causes: white-coat effect (use home/ABPM), inadequate dosing, wrong diuretic for renal function (need loop at eGFR < 30), and drug interactions (NSAIDs, OCPs, decongestants). Always rule out pseudoresistance before adding a fourth drug or chasing secondary causes.
What's the spironolactone evidence in resistant HTN?
PATHWAY-2, 2015: in patients with resistant HTN already on ACEi/ARB + CCB + thiazide, spironolactone reduced home SBP significantly more than bisoprolol or doxazosin. This established spironolactone as the preferred fourth-line agent. Mechanism: most resistant HTN involves some aldosterone-driven sodium retention, even without overt primary aldosteronism. Watch hyperkalemia (recheck K⁺ at 3 days, 1 week, then monthly).
Why avoid ACEi monotherapy in Black patients?
ALLHAT 2002 and other trials: ACEi monotherapy lowers BP less effectively in Black patients compared to non-Black. Mechanistic explanation: Black patients tend to have lower-renin HTN, which responds better to thiazides and CCBs (volume/vascular drivers) than to RAAS inhibition. ACEi/ARB are still appropriate when there's a compelling indication -concomitant HFrEF, CKD with proteinuria, or DM with albuminuria -but as monotherapy for uncomplicated HTN in Black patients, thiazide or CCB is preferred.
Clinical Examples
📋 Case 1, New Stage 2 HTN, No Comorbidities
Patient: 52F with no PMH presents for routine physical. BP 156/96 today, 152/94 last visit (2 weeks ago). Home BP averaging 150/92 over the past month. BMI 31. Non-Black. No DM or CKD.
Labs: BMP normal, K⁺ 4.0, eGFR 88, A1c 5.6%, lipids normal, UACR < 30 mg/g. ECG: no LVH. ASCVD 10-yr risk 7%.
Plan:
- Diagnosis confirmed -stage 2 HTN by office plus home readings.
- Lifestyle: DASH diet, sodium < 2 g/day, 150 min/week aerobic exercise, weight loss target 5-10%.
- Two-drug combination (BP > 20/10 above target): start chlorthalidone 12.5 mg + lisinopril 10 mg, ideally as a single-pill combination.
- Follow-up at 2-4 weeks with BMP and BP recheck. Target home average < 130/80.
Teaching point: Stage 2 HTN warrants two drugs from day 1. Single-pill combinations dramatically improve adherence. Confirm diagnosis with home or ABPM data before committing to lifelong therapy.
📋 Case 2, Resistant HTN Workup
Patient: 58M, HTN ×8 years, on lisinopril 40 mg, amlodipine 10 mg, HCTZ 25 mg. Office BP 162/98 today. Home BP averages 158/96. Adherent (verified pill counts and pharmacy refills).
Labs: K⁺ 3.3, eGFR 72, BMP otherwise normal. UACR 45 mg/g. No NSAID/decongestant use. BMI 34.
Plan:
- Pseudoresistance ruled out -adherent, home BP confirms, no offending drugs.
- Switch HCTZ → chlorthalidone 25 mg for better 24h control.
- Screen for secondary causes: morning aldosterone-to-renin ratio (low K⁺ raises suspicion for primary aldosteronism), STOP-BANG (BMI 34 high pretest for OSA), TSH.
- Add spironolactone 25 mg daily as fourth agent (PATHWAY-2 evidence). Recheck K⁺ in 1 week.
- Sleep study referral for OSA evaluation.
Teaching point: True resistant HTN demands secondary cause workup AND optimization of existing therapy (chlorthalidone over HCTZ). Spironolactone is the preferred fourth drug. Hypokalemia plus HTN should always raise primary aldosteronism on the differential.
📋 Case 3, HTN in Pregnancy
Patient: 29F, 22 weeks pregnant, BP 148/96 at routine prenatal visit. No proteinuria. No history of HTN. Asymptomatic.
Plan:
- Recheck BP and confirm with home or repeat readings. Treat at threshold ≥ 140/90 per CHAP, 2022.
- Workup: 24-hour urine protein or UACR (rule out preeclampsia), CBC, LFTs, BMP, uric acid.
- Drug choice: labetalol (preferred) or nifedipine ER. Methyldopa is older alternative. Start labetalol 100 mg BID, titrate.
- STOP any ACEi / ARB / ARNI / direct renin inhibitor -teratogenic, especially 2nd-3rd trimester (oligohydramnios, renal failure, skull defects).
- OB co-management for preeclampsia surveillance.
Teaching point: Treat chronic HTN in pregnancy at 140/90 (CHAP 2022 changed practice). Labetalol, nifedipine, methyldopa are safe; RAAS inhibitors are absolutely contraindicated.
📣 Sample Presentation
One-Liner
"Mr. Lopez is a 58-year-old with stage 2 HTN, on triple therapy at maximum doses, with home BP averaging 158/96 despite verified adherence. Workup for resistant HTN today."
Plan
(1) Switch HCTZ to chlorthalidone. (2) Send aldosterone-to-renin ratio after holding MRA/diuretics for 2 weeks. (3) STOP-BANG and sleep study referral (BMI 34). (4) Add spironolactone 25 mg daily after K⁺ confirmed < 5.0. (5) Recheck BMP at 1 week, BP and home log at 4 weeks.
⚡ Summary
Summary
Confirm Before You Treat
Stage 1 is 130 to 139 or 80 to 89; stage 2 is 140/90 or above (ACC/AHA 2017). Confirm with out-of-office readings, home monitoring or ambulatory monitoring, before labeling anyone hypertensive. White coat hypertension is common, and masked hypertension is dangerous, so the clinic reading alone commits some patients to lifelong therapy they do not need and reassures others who do.
Start Drugs by Stage and Risk, Not by Number Alone
Stage 1 with ASCVD risk below 10%: lifestyle for 3 to 6 months. Stage 1 with risk 10% or above, or with diabetes, CKD or established cardiovascular disease: start medication. Stage 2: start two agents. Recheck and titrate at 2 to 4 weeks rather than at 3 months, since slow titration is why so many patients remain uncontrolled for years.
Four First-Line Classes, Chosen by Comorbidity
Thiazide, ACE inhibitor or ARB, and dihydropyridine calcium channel blocker. ACE inhibitor or ARB for diabetes with albuminuria, CKD and HFrEF. Beta blockers are not first line for uncomplicated hypertension, and are used when there is a compelling indication such as ischemic heart disease, heart failure or rate control. Never combine an ACE inhibitor with an ARB.
Prefer Chlorthalidone and Combine Rationally
Chlorthalidone is longer-acting and more potent than hydrochlorothiazide at equivalent doses. ACE inhibitor or ARB plus a calcium channel blocker beat ACE inhibitor plus thiazide on cardiovascular outcomes (ACCOMPLISH). Use single-pill combinations, which measurably improve adherence, and adherence is the dominant determinant of control.
Know Why SPRINT and ACCORD Split
SPRINT showed a systolic target below 120 reduced events and mortality in high-risk non-diabetic patients, using unattended automated readings that run lower than routine clinic values. ACCORD-BP found no benefit in diabetics. So an intensive target is reasonable in selected high-risk non-diabetic patients, measured the same way SPRINT measured it, and less so in diabetes and in the frail elderly where falls and syncope rise.
Non-Adherence Is the Number One Cause of Apparent Resistance
Before working up resistant hypertension, confirm the patient is actually taking the drugs and that the technique of measurement is correct: right cuff size, seated, back supported, arm at heart level, no talking. Pseudoresistance from non-adherence, white coat effect and poor technique accounts for a large share of referrals.
Screen for Secondary Causes in the Right Patients
Onset before 30 or after 55, resistant hypertension on three drugs including a diuretic, hypokalemia, an abrupt loss of control, or an adrenal mass. Primary aldosteronism is the commonest and is heavily under-diagnosed, and the 2025 guidance is to screen every hypertensive patient. Also consider renal artery stenosis, OSA, pheochromocytoma, thyroid disease, Cushing syndrome and coarctation.
Do Not Forget the Drug Causes and Lifestyle
NSAIDs, decongestants, oral contraceptives, stimulants, steroids, calcineurin inhibitors, licorice, alcohol and cocaine. Sodium restriction, the DASH diet, weight loss, exercise and alcohol reduction each lower systolic pressure by several mmHg and are additive, so together they are equivalent to a drug. Home blood pressure monitoring improves control and is a genuine intervention, not just a measurement.
📄 One Pager
Text version
Outpatient HTN - Quick Reference Card
Print this page (Ctrl/Cmd + P) for a condensed reference.
OUTPATIENT HYPERTENSION - AT A GLANCE
📊 Stage: Stage 1 130-139/80-89 (treat if ASCVD ≥ 10% / DM / CKD / CV disease). Stage 2 ≥ 140/90 (treat all). Confirm with home/ABPM.
🎯 Target: < 130/80 most. < 140/90 frail elderly or pregnancy.
💊 First-line: Chlorthalidone, amlodipine, or ACEi/ARB. Black patients: thiazide or CCB first. Start 2 drugs if > 20/10 above target.
🏥 Compelling indication: HFrEF → 4 pillars. CKD/DM proteinuria → ACEi/ARB + SGLT2i. Post-MI → BB + ACEi. AFib → BB or non-DHP CCB.
⚠️ Resistant HTN: 3 drugs incl diuretic, still uncontrolled. (1) Confirm adherence + chlorthalidone over HCTZ. (2) Workup secondary causes (aldo, OSA, RAS). (3) Add spironolactone (PATHWAY-2).
🤰 Pregnancy: Labetalol, nifedipine, methyldopa. Treat ≥ 140/90 (CHAP 2022). NO ACEi/ARB/MRA.
🥗 Lifestyle: DASH + Na < 2g + weight + exercise. Stacked = 20+ mmHg.
🎯 Target: < 130/80 most. < 140/90 frail elderly or pregnancy.
💊 First-line: Chlorthalidone, amlodipine, or ACEi/ARB. Black patients: thiazide or CCB first. Start 2 drugs if > 20/10 above target.
🏥 Compelling indication: HFrEF → 4 pillars. CKD/DM proteinuria → ACEi/ARB + SGLT2i. Post-MI → BB + ACEi. AFib → BB or non-DHP CCB.
⚠️ Resistant HTN: 3 drugs incl diuretic, still uncontrolled. (1) Confirm adherence + chlorthalidone over HCTZ. (2) Workup secondary causes (aldo, OSA, RAS). (3) Add spironolactone (PATHWAY-2).
🤰 Pregnancy: Labetalol, nifedipine, methyldopa. Treat ≥ 140/90 (CHAP 2022). NO ACEi/ARB/MRA.
🥗 Lifestyle: DASH + Na < 2g + weight + exercise. Stacked = 20+ mmHg.
Related Topics
ACS OverviewAortic DissectionAortic StenosisArrhythmiasAtrial FibrillationCardiac Tamponade